Oslo, Norway 17 December 2024, Circio Holding ASA (OSE: CRNA) Reference is made to the stock exchange announcement on 4 December 2024 regarding commencement of the exercise period for Warrants from 4-18 December 2024 (the “Exercise Period“).
Erik Digman Wiklund, CEO of Circio, has on 17 December 2024 applied to be allocated an additional 115,867 Warrants, for the subscription of 115,867 New Shares in the Company at a price per New Share of NOK 0.60. The allocation of Warrants and private placement shares is subject to allocation by the board of directors of the Company.
On 5 December 2024, Erik Digman Wiklund exercised a total of 140,400 Warrants, for the allocation of 140,400 New Shares in the Company at a price per New Share of NOK 0.60.
A total of 13,864,852 warrants (the “Warrants”) were issued and registered with the Norwegian Register of Business Enterprises on 26 July 2024 in relation to the rights issue completed in July 2024. Each Warrant gives the holder a right to subscribe for one new share in the Company at an exercise price per share of NOK 0.60 during the exercise period (the “New Shares“).
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com
About Circio
Building next generation RNA technology for nucleic acid medicine
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression platform for novel DNA, RNA and viral therapeutics. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA inside cells, which can be deployed in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. The circVec platform has demonstrated up to 15-fold enhanced and more significantly more durable protein expression vs. classic mRNA vector systems and has the potential to become a new gold-standard platform technology for nucleic acid and viral therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials: RAS-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway. These studies are being run through academic and industry collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.